PPAR Medicines and Human Disease: The ABCs of It All
暂无分享,去创建一个
[1] Merlin C. Thomas,et al. Direct antiatherosclerotic effects of PPAR agonists , 2009, Current opinion in lipidology.
[2] A. Tall,et al. Cholesterol efflux pathways and other potential mechanisms involved in the athero‐protective effect of high density lipoproteins , 2008, Journal of internal medicine.
[3] Darrell R. Abernethy,et al. International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.
[4] W. Haefeli,et al. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. , 2004, Biochemical pharmacology.
[5] W. Haefeli,et al. Interaction of Thiazolidinediones (Glitazones) with the ATP-Binding Cassette Transporters P-Glycoprotein and Breast Cancer Resistance Protein , 2009, Pharmacology.
[6] Karim Benkirane,et al. Vascular and Cardiac Effects in Hypertension , 2022 .
[7] B. Spiegelman,et al. International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.
[8] Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001 .
[9] D. Kelsell,et al. Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. , 2005, American journal of human genetics.
[10] A. Tall,et al. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.
[11] P. Elias,et al. Regulation of ABCA1 expression in human keratinocytes and murine epidermis Published, JLR Papers in Press, July 6, 2006. , 2006, Journal of Lipid Research.
[12] B. Staels,et al. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. , 2003, The Biochemical journal.
[13] R. Bendayan,et al. Regulation of Breast Cancer Resistant Protein by Peroxisome Proliferator-Activated Receptor α in Human Brain Microvessel Endothelial Cells , 2012, Molecular Pharmacology.
[14] M. Haber,et al. Role of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer , 2007, IUBMB life.
[15] J. Wittes,et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.
[16] A. Vaughan,et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. , 1999, The Journal of clinical investigation.
[17] Chava Kimchi-Sarfaty,et al. P-glycoprotein: from genomics to mechanism , 2003, Oncogene.
[18] J. Peters,et al. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention , 2012, Nature Reviews Cancer.
[19] A. Tall,et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[20] L. Doyle,et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. , 2001, Biochemical and biophysical research communications.
[21] J. Plutzky. Inflammation in Atherosclerosis and Diabetes Mellitus , 2004, Reviews in Endocrine and Metabolic Disorders.
[22] S. Kliewer,et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[23] Curtis D. Klaassen,et al. INDUCTION OF THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN FAMILY OF TRANSPORTERS BY CHEMICAL ACTIVATORS OF RECEPTOR-MEDIATED PATHWAYS IN MOUSE LIVER , 2005, Drug Metabolism and Disposition.
[24] R. Paoletti,et al. Advances in Lipid Research , 1988 .
[25] R. Johnstone,et al. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[27] M. Vázquez-Carrera,et al. Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. , 2004, Biochemical pharmacology.
[28] T. Willson,et al. Triglyceride:High-Density Lipoprotein Cholesterol Effects in Healthy Subjects Administered a Peroxisome Proliferator Activated Receptor &dgr; Agonist , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[29] J. Auwerx,et al. Cross-Talk between Fatty Acid and Cholesterol Metabolism Mediated by Liver X Receptor-α , 2000 .
[30] K. Yoshizato,et al. Bezafibrate induces multidrug‐resistance P‐Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[31] Kazumitsu Ueda,et al. Fenofibric Acid, an Active Form of Fenofibrate, Increases Apolipoprotein A-I–Mediated High-Density Lipoprotein Biogenesis by Enhancing Transcription of ATP-Binding Cassette Transporter A1 Gene in a Liver X Receptor–Dependent Manner , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[32] S. Jameson,et al. Expression of the transcription factor lung Krüppel-like factor is regulated by cytokines and correlates with survival of memory T cells in vitro and in vivo. , 1999, Journal of immunology.
[33] D. Mogilenko,et al. PPARγ activates ABCA1 gene transcription but reduces the level of ABCA1 protein in HepG2 cells. , 2010, Biochemical and biophysical research communications.
[34] J. Schellens,et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.
[35] E. Barta,et al. Peroxisome Proliferator-activated Receptor γ-regulated ABCG2 Expression Confers Cytoprotection to Human Dendritic Cells* , 2006, Journal of Biological Chemistry.
[36] J. Berger,et al. PPARs: therapeutic targets for metabolic disease. , 2005, Trends in pharmacological sciences.
[37] Z. Varghese,et al. J Am Soc Nephrol 14: 593–600, 2003 PPAR Agonists Protect Mesangial Cells from Interleukin 1�- Induced Intracellular Lipid Accumulation by Activating the , 2022 .
[38] S. Salomone. Pleiotropic Effects of Glitazones: A Double Edge Sword? , 2011, Front. Pharmacol..
[39] J. Auwerx,et al. Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients , 1997, Diabetes.
[40] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[41] Jingqing Yang,et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. , 2005, Cancer research.
[42] S. Kaye. Reversal of drug resistance in ovarian cancer: where do we go from here? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] A. Rzhetsky,et al. The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.
[44] T. Rajkumar,et al. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line , 2008, Anti-cancer drugs.
[45] A. Adem,et al. Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators , 2011, The open medicinal chemistry journal.
[46] Michael Müller,et al. Gene expression of transporters and phase I/II metabolic enzymes in murine small intestine during fasting , 2007, BMC Genomics.
[47] W. Wahli,et al. New insights into the role of PPARs. , 2011, Prostaglandins, leukotrienes, and essential fatty acids.
[48] K. Motojima,et al. PPARα Agonists Positively and Negatively Regulate the Expression of Several Nutrient/Drug Transporters in Mouse Small Intestine , 2007 .
[49] R. Evans,et al. PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.
[50] M. Hamburg,et al. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. , 2010, The New England journal of medicine.
[51] B. Barna,et al. Restoration of PPARγ reverses lipid accumulation in alveolar macrophages of GM-CSF knockout mice. , 2011, American journal of physiology. Lung cellular and molecular physiology.
[52] C. Atalay,et al. Multidrug Resistance in Locally Advanced Breast Cancer , 2006, Tumor Biology.
[53] T. Willson,et al. The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.
[54] C. Fielding,et al. Molecular physiology of reverse cholesterol transport. , 1995, Journal of lipid research.
[55] J. Tanabe,et al. Effects of combined PPARγ and PPARα agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat , 2008 .
[56] Y. Uehara,et al. Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARγ/LXRα pathway: findings from in vitro and ex vivo studies. , 2011, Atherosclerosis.
[57] M. Price,et al. New strategies in managing and preventing atherosclerosis: focus on HDL. , 2002, Reviews in cardiovascular medicine.
[58] T. Harkness,et al. Troglitazone reverses the multiple drug resistance phenotype in cancer cells , 2009, Drug design, development and therapy.
[59] D. Rees,et al. ABC transporters: the power to change , 2009, Nature Reviews Molecular Cell Biology.
[60] S. Yokoyama,et al. On the mechanism for PPAR agonists to enhance ABCA1 gene expression. , 2009, Atherosclerosis.
[61] M. Jaye,et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.
[62] S. Jane,et al. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux , 2004, Cell Death and Differentiation.
[63] P. Edwards,et al. Regulation of ABCG1 expression in human keratinocytes and murine epidermis[S] , 2006, Journal of Lipid Research.
[64] R. Ringseis,et al. Conjugated Linoleic Acid Isomers Reduce Cholesterol Accumulation in Acetylated LDL-Induced Mouse RAW264.7 Macrophage-Derived Foam Cells , 2008, Lipids.
[65] E. Araki,et al. Telmisartan Exerts Antiatherosclerotic Effects by Activating Peroxisome Proliferator-Activated Receptor-&ggr; in Macrophages , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[66] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.
[67] H. Kim,et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[68] A. Rigotti,et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. , 1996, The Biochemical journal.
[69] R. Ringseis,et al. 13-hydroxy linoleic acid increases expression of the cholesterol transporters ABCA1, ABCG1 and SR-BI and stimulates apoA-I-dependent cholesterol efflux in RAW264.7 macrophages , 2011, Lipids in Health and Disease.
[70] G. Gibbons,et al. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. , 2003, Journal of lipid research.
[71] A. Tedgui,et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. , 2000, Circulation.
[72] Jie Zhou 周 洁,et al. Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARγ activation by troglitazone , 2010, Journal of Huazhong University of Science and Technology [Medical Sciences].
[73] D. Arnett,et al. Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. , 2010, Molecular genetics and metabolism.
[74] I. Issemann,et al. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.
[75] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.
[76] V. Preedy,et al. Randomized Controlled Trial , 2010 .
[77] M. Kool,et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.
[78] I. Holen,et al. Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies , 2011, International journal of breast cancer.
[79] Philippe Chavatte,et al. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. , 2012, Journal of medicinal chemistry.
[80] H. Brewer,et al. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[81] Yong-Xu Wang. PPARs: diverse regulators in energy metabolism and metabolic diseases , 2010, Cell Research.
[82] M. Akiyama. Pathomechanisms of harlequin ichthyosis and ABCA transporters in human diseases. , 2006, Archives of dermatology.
[83] W. Wahli,et al. PPARs in diseases: control mechanisms of inflammation. , 2005, Current medicinal chemistry.
[84] Y. Sugiyama,et al. Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. , 2004, Journal of lipid research.
[85] B. Staels,et al. Peroxisome proliferator-activated receptor α (PPARα)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice , 2004 .
[86] C. Glass,et al. Conditional Disruption of the Peroxisome Proliferator-Activated Receptor γ Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux , 2002, Molecular and Cellular Biology.
[87] M. Vázquez-Carrera,et al. Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. , 2006, Biochemical pharmacology.
[88] H. Choi,et al. The Effect of PPARα and PPARγ Ligands on Inflammation and ABCA1 Expression in Cultured Gallbladder Epithelial Cells , 2008, Digestive Diseases and Sciences.
[89] J. R. McMillan,et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. , 2005, The Journal of clinical investigation.
[90] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[91] B. Staels,et al. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. , 2003, Gastroenterology.
[92] Y. Nishiwaki,et al. Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[93] Jeffrey S Moffit,et al. Induction of Hepatic Transporters Multidrug Resistance-Associated Proteins (Mrp) 3 and 4 by Clofibrate Is Regulated by Peroxisome Proliferator-Activated Receptor α , 2006, Journal of Pharmacology and Experimental Therapeutics.
[94] W. K. Roberts,et al. Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. , 1997, Biochemistry.
[95] P. Barter,et al. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[96] R. Evans,et al. A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .
[97] P. Elias,et al. Ichthyosis update: towards a function-driven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders. , 2007, Advances in dermatology.
[98] C. Klaassen,et al. Regulation of rat multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.
[99] B. Seed,et al. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.
[100] J. Peters,et al. Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[101] M. J. van de Vijver,et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.
[102] K. Brouwer,et al. Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[103] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[104] Liyan Yu,et al. Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPARγ-LXRα-ABCA1 pathway. , 2011, Biochemical and biophysical research communications.
[105] C. Weber,et al. Atherosclerosis: current pathogenesis and therapeutic options , 2011, Nature Medicine.
[106] P. Elias,et al. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. , 2006, The Journal of investigative dermatology.
[107] S. Cole,et al. Mammalian multidrug-resistance proteins (MRPs). , 2011, Essays in biochemistry.
[108] Christopher K. Glass,et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.
[109] C. Glass,et al. PPARs and molecular mechanisms of transrepression. , 2007, Biochimica et biophysica acta.
[110] D. Curiel,et al. A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. , 2008, Blood.
[111] P. Libby,et al. Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro , 1998 .
[112] P. Elias,et al. Ceramide Stimulates ABCA12 Expression via Peroxisome Proliferator-activated Receptor δ in Human Keratinocytes* , 2009, The Journal of Biological Chemistry.
[113] J. Piette,et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 , 1999, Nature Genetics.
[114] Elisabetta Poluzzi,et al. Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting , 2011, Diabetes Care.
[115] S. Yokoyama,et al. Effects of Fibrate Drugs on Expression of ABCA1 and HDL Biogenesis in Hepatocytes , 2008, Journal of cardiovascular pharmacology.
[116] T. Litman,et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.
[117] P. Elias,et al. PPAR and LXR activators regulate ABCA12 expression in human keratinocytes. , 2008, The Journal of investigative dermatology.
[118] Robert A Hegele,et al. Retinoid X receptor heterodimers in the metabolic syndrome. , 2005, The New England journal of medicine.
[119] S. Cole,et al. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. , 2006, Physiological reviews.
[120] H. Uno,et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. , 2010, Blood.
[121] H. Nakauchi,et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.
[122] B. Spiegelman. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.
[123] B. Staels,et al. Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* , 1998, The Journal of Biological Chemistry.
[124] P. Elias,et al. The biochemistry and function of stratum corneum lipids. , 1991, Advances in lipid research.
[125] J. Fletcher,et al. ABC transporters in cancer: more than just drug efflux pumps , 2010, Nature Reviews Cancer.
[126] M. Lazar,et al. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.